Summary
Santaris Pharma A/S (Santaris) is a biopharmaceutical company. The company discovers and develops RNA-targeted therapies. Its products pipeline includes SPC2968, SPC4955 and miravirsen. The company uses LNA drug platform to identify and advance antisense drug candidates. Santaris offers products for the treatment of infectious diseases, oncology solid tumors, metabolic disorders and rare genetic disorders. It also develops transformational therapeutics across multiple disease areas. The company offers small molecule and protein therapeutic technologies. It partners with Bristol-Myers Squibb, GlaxoSmithKline, Isarna, miRagen, Pfizer, RaNA, Roche, and Shire. It has a presence in the US. Santaris is headquartered in Horsholm, Denmark.
Santaris Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
Santaris Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 5
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 6
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 8
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Santaris Pharma Raises US$12 Million In Venture Financing 10
Partnerships 12
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 12
Santaris Enters Into Co-Development Agreement With Roche For RNA-Targeted Drugs 13
Shire Extends Research Agreement With Santaris Pharma For LNA Drugs 14
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 15
Santaris Pharma Expands Its Collaboration With Pfizer 16
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics 18
Shire Enters Into Research Agreement With Santaris Pharma 19
Wyeth Pharma Enters Into An Agreement With Santaris Pharma 20
Licensing Agreements 21
Isarna Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop Oligonucleotides For TGF-?-Mediated Diseases 21
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 22
Santaris Pharma Expands Licensing Agreement With miRagen Therapeutics For LNA-Drugs 23
Research Ventures & Licensing Enters Into Licensing Agreement With Santaris Pharma 24
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital 25
Santaris Pharma A/S - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List Of Tables
List of Tables
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Key Facts 1
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 1
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 1
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 1
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
Santaris Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 5
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 6
Santaris Pharma A/S, Deals By Therapy Area, 2008 to YTD 2014 7
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 8
Santaris Pharma Raises US$12 Million In Venture Financing 10
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 12
Santaris Enters Into Co-Development Agreement With Roche For RNA-Targeted Drugs 13
Shire Extends Research Agreement With Santaris Pharma For LNA Drugs 14
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 15
Santaris Pharma Expands Its Collaboration With Pfizer 16
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics 18
Shire Enters Into Research Agreement With Santaris Pharma 19
Wyeth Pharma Enters Into An Agreement With Santaris Pharma 20
Isarna Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop Oligonucleotides For TGF-?-Mediated Diseases 21
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 22
Santaris Pharma Expands Licensing Agreement With miRagen Therapeutics For LNA-Drugs 23
Research Ventures & Licensing Enters Into Licensing Agreement With Santaris Pharma 24
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital 25
Santaris Pharma A/S, Key Competitors 26
Santaris Pharma A/S, Key Employees 27
Santaris Pharma A/S, Other Locations 28
List Of Figures
List of Figures
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 1
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 4
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 5
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 6
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 7
